Compare DRD & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | IMNM |
|---|---|---|
| Founded | 1895 | 2006 |
| Country | South Africa | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.8B |
| IPO Year | N/A | 2020 |
| Metric | DRD | IMNM |
|---|---|---|
| Price | $30.47 | $23.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $27.50 | $26.89 |
| AVG Volume (30 Days) | 457.3K | ★ 1.2M |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | ★ 68.66 | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $443,674,785.00 | $9,679,000.00 |
| Revenue This Year | $18.10 | N/A |
| Revenue Next Year | $25.92 | N/A |
| P/E Ratio | $21.54 | ★ N/A |
| Revenue Growth | ★ 26.26 | N/A |
| 52 Week Low | $8.38 | $5.15 |
| 52 Week High | $33.31 | $20.80 |
| Indicator | DRD | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 58.43 | 72.30 |
| Support Level | $28.04 | $18.81 |
| Resistance Level | $33.31 | $20.80 |
| Average True Range (ATR) | 1.31 | 1.45 |
| MACD | 0.15 | 0.22 |
| Stochastic Oscillator | 52.01 | 83.69 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.